Clinical trial
A Multi-centered, Randomized, Controlled Study to Evaluate the Safety and Immunogenicity of Combined Immunization of 23-valent Pneumococcal Polysaccharide Vaccine (PPV23) and Quadrivalent Inactivated Influenza Vaccine (IIV4)
NCT04559204 is registered in ClinicalTrials.gov with China National Biotec Group Company Limited as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multi-centered, Randomized, Controlled Study to Evaluate the Safety and Immunogenicity of Combined Immunization of 23-valent Pneumococcal Polysaccharide Vaccine (PPV23) and Quadrivalent Inactivated Influenza Vaccine (IIV4)
- Lead sponsor
- China National Biotec Group Company Limited
- Phase
- Phase 4
- Overall status
- Completed
- Start date
- September 11, 2020
- Completion date
- October 9, 2021
- Enrollment
- 1,224 (actual)
- Sites
- 4
Conditions
As the registry lists them; a condition with its own page is linked.